

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **DESIGNATION OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (“**Directors**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Board has designated Mr. Fung Che Wai, Anthony, an independent non-executive Director, to assume the position of the lead independent non-executive Director (“**Lead INED**”) with effect from August 15, 2025 for the purpose of adopting a high standard of corporate governance. The Lead INED will not have a separate or higher level of responsibility or liability relative to other independent non-executive Directors. He will serve as a channel of communication to enable shareholders to understand the actions taken by independent non-executive Directors (“**INEDs**”) in the performance of their responsibilities, as an intermediary between Directors and shareholders and enhance the communications among the INEDs and between the INEDs and the rest of the Board. The Lead INED is not an executive position in the Company and does not have any management role in the Group.

Mr. Fung Che Wai, Anthony’s other positions in the Board and the relevant Board committees remain unchanged.

The above designation of the Lead INED is implemented in response to the amended Corporate Governance Code as contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which came into effect on 1 July 2025. The Board considers that sound corporate governance plays a vital role in the overall performance of the Company and believes that implementing these changes could strengthen the Board’s effectiveness and diversity, and further enhance good corporate governance practices across the Company.

The Board would like to take this opportunity to welcome Mr. Fung Che Wai, Anthony in his new role in the Board.

By Order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**

*Chairman of the Board and Executive Director*

Hong Kong, August 15, 2025

*As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.*